Maribavir shortage — NO supply status & alternatives

Maribavir

—

🇦🇺 AUST R 380132 · Takeda Pharmaceuticals Australia Pty Ltd

In supply · Australia

Livtencity

In supply · 🇦🇺 Australia · short in🇳🇴 NO

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Controlled substance
Active ingredient (INN)	Maribavir
Brand names	Livtencity
Therapeutic category	Auto-created by NoMA (Norwegian Medicines Agency / DMP) scraper

Marketing-authorisation holders	Takeda Pharmaceuticals Australia Pty Ltd

Registrations on file	1

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

5 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Moderate concentration risk

Maithri Drugs Private LTDHonour Lab LTDMsn Life Sciences Private LTDQilu Pharmaceutical CO LTDSun Pharmaceutical Industries LTD

Manufacturing countries: India, China · Source: FDA List of Drug Master Files

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders1 registration · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
LIVTENCITY maribavir	200 mg	—	🇦🇺 AU	Takeda Pharmaceuticals Australia Pty Ltd	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.